Место внутривенного иммуноглобулина при ревматических заболеваниях
https://doi.org/10.14412/1996-7012-2015-4-59-67
Аннотация
Терапия внутривенным человеческим иммуноглобулином (ВВИГ) была и продолжает оставаться необходимой при ряде заболеваний. В то же время доказательная база применения ВВИГ в ревматологии крайне мала. Клинический опыт показывает, что ВВИГ эффективен при тромбоцитопенической пурпуре, синдроме Гийена–Барре и хронической воспалительной демиелинизирующей полиневропатии, развившихся на фоне ревматических заболеваний, таких как системная красная волчанка, воспалительные миопатии и ассоциированные с антинейтрофильными цитоплазматическими антителами васкулиты. В обзоре рассмотрены показания к назначению ВВИГ, режим дозирования, преимущества и нежелательные реакции, приведен анализ отечественной и зарубежной литературы по данному вопросу
Об авторах
Н. В. Середавкина
ФГБНУ Научно-исследовательский институт ревматологии им. В.А. Насоновой
Россия
115522, Москва, Каширское шоссе, 34А
Россия
115522, Москва, Каширское шоссе, 34А
Т. М. Решетняк
ФГБНУ Научно-исследовательский институт ревматологии им. В.А. Насоновой
Россия
115522, Москва, Каширское шоссе, 34А
Россия
115522, Москва, Каширское шоссе, 34А
Е. Л. Насонов
ФГБНУ Научно-исследовательский институт ревматологии им. В.А. Насоновой
Россия
115522, Москва, Каширское шоссе, 34А
Россия
115522, Москва, Каширское шоссе, 34А
Литература
1. Gelfand EW. Intravenous immune globulin in autoimmune and inflammatory diseases. N Engl J Med. 2012;367(21):2015-25. doi: 10.1056/NEJMra1009433.
2. Durandy A, Kaveri SV, Kuijpers TW, et al. Intravenous immunoglobulins – understanding properties and mechanisms. Clin Exp Immunol. 2009;158 Suppl 1:2-13. doi: 10.1111/j.1365-2249.2009.04022.x.
3. Gupta M, Noel GJ, Schaefer M, et al. Cytokine modulation with immune gammaglobulin in peripheral blood of normal children and its implications in Kawasaki disease treatment. J Clin Immunol. 2001;21(3):193-9. doi: 10.1023/A:1011039216251.
4. Basta M. Ambivalent effect of immunoglobulins on the complement system: activation versus inhibition. Mol Immunol. 2008;45(16):4073-9. doi: 10.1016/j.molimm.2008.07.012.
5. Shoenfeld Y, Katz U. IVIg therapy in autoimmunity and related disorders: our experience with a large cohort of patients. Autoimmunity. 2005;38(2):123-37. doi: 10.1080/08916930500059633.
6. Le Pottier L, Sapir T, Bendaoud B, et al. Intravenous immunoglobulin and cytokines: focus on tumor necrosis factor family members BAFF and APRIL. Ann N Y Acad Sci. 2007;1110:426-32. doi: 10.1196/annals.1423.044.
7. Mulhearn B, Bruce IN. Indications for IVIG in rheumatic diseases. Rheumatology (Oxford). 2015;54(3):383-91. doi: 10.1093/rheumatology/keu429.
8. Zandman-Goddard G, Blank M, Shoenfeld Y. Intravenous immunoglobulins in systemic lupus erythematosus: from the bench to the bedside. Lupus. 2009;18(10):884-8. doi: 10.1177/0961203309106921.
9. Katz U, Achiron A, Sherer Y, et al. Safety of intravenous immunoglobulin (IVIG) therapy. Autoimmun Rev. 2007;6(4):257-9. doi: 10.1016/j.autrev.2006.08.011.
10. Zandman-Goddard G, Levy Y, Shoenfeld Y. Intravenous immunoglobulin therapy and systemic lupus erythematosus. Clin Rev Allergy Immunol. 2005;29(3):219-28. doi: 10.1385/CRIAI:29:3:219.
11. Jean R, Bastard E, Cretel E, et al. Intravenous immunoglobulin and antiphospholipid syndrome: comment on the article by Erkan et al. Arthritis Rheum. 2004;50(8):2711; author reply 2711-3. doi: 10.1002/art.20387.
12. Wolberg AS, Kon RH, Monroe DM, et al. Coagulation factor XI is a contaminant in intravenous immunoglobulin preparations. Am J Hematol. 2000;65(1):30-4. doi: 10.1002/1096-8652(200009)65: 1<30::AID-AJH5>3.0.CO;2-J.
13. Gross KL, Lu NZ, Cidlowski JA. Molecular mechanisms regulating glucocorticoid sensitivity and resistance. Mol Cell Endocrinol. 2009;300(1-2):7-16. doi: 10.1016/j.mce.2008.10.001.
14. Zandman-Goddard G, Krauthammer A, Shoenfeld Y. The steroidsparing effect of IVIG. Expert Rev Clin Immunol. 2007;3(5):773-80. doi: 10.1586/1744666X.3.5.773.
15. Levy Y, Sherer Y, Ahmed A, et al. A study of 20 SLE patients with intravenous immunoglobulin-clinical and serological response. Lupus. 1999;8(9):705-12. doi: 10.1191/096120399678841007.
16. Vaitla PM, McDermott EM. The role of high-dose intravenous immunoglobulin in rheumatology. Rheumatology (Oxford). 2010;49(6):1040-8. doi: 10.1093/rheumatology/keq021.
17. Sherer Y, Kuechler S, Jose Scali J, et al. Low dose intravenous immunoglobulin in systemic lupus erythematosus: analysis of 62 cases. Isr Med Assoc J. 2008;10(1):55-7.
18. Zandman-Goddard G, Krauthammer A, Levy Y, et al. Long-term therapy with intravenous immunoglobulin is beneficial in patients with autoimmune diseases. Clin Rev Allergy Immunol. 2012;42(2):247-55. doi: 10.1007/s12016-011-8278-7.
19. Levy Y, Sherer Y, George J, et al. Intravenous immunoglobulin treatment of lupus nephritis. Semin Arthritis Rheum.2000;29(5):321-7. doi: 10.1016/S0049-0172(00)80018-9.
20. Francioni C, Galeazzi M, Fioravanti A, et al. Long-term IVIG treatment in systemic lupus erythematosus. Clin Exp Rheumatol. 1994;12(2):163-8.
21. Caccavo D, Vaccaro F, Ferri GM, et al. Antiidiotypes against antiphospholipid antibodies are present in normal polyspecific immunoglobulins for therapeutic use. J Autoimmun. 1994;7(4):537-48. doi: 10.1006/jaut.1994.1039.
22. Shoenfeld Y, Rauova L, Gilburd B, et al. Efficacy of IVIG affinitypurified anti- doublestranded DNA anti-idiotypic antibodies in the treatment of an experimental murine model of systemic lupus erythematosus. Int Immunol. 2002;14(11):1303-11. doi: 10.1093/intimm/dxf099.
23. Krause I, Blank M, Sherer Y, et al. Induction of oral tolerance in experimental antiphospholipid syndrome by feeding with polyclonal immunoglobulins. Eur J Immunol. 2002;32(12):3414-24. doi: 10.1002/1521-4141(200212)32:12<3414::AIDIMMU3414>3.0.CO;2-F.
24. Su J, Hua X, Concha H, et al. Natural antibodies against phosphorylcholine as potential protective factors in SLE. Rheumatology (Oxford). 2008;47(8):1144-50. doi: 10.1093/rheumatology/ken120.
25. Arnal C, Piette JC, Leone J, et al. Treatment of severe immune thrombocytopenia associated with systemic lupus erythematosus: 59 cases. J Rheumatol. 2002;29(1):75-83.
26. Santiago-Casas Y, Peredo RA, Vila LM. Efficacy of low-dose intravenous yclophosphamide in systemic lupus erythematosus presenting with Guillain-Barre syndrome-like acute axonal neuropathies: report of two cases. Lupus. 2013;22(3):324-7. doi: 10.1177/0961203313476358.
27. Cimaz R, Spence DL, Hornberger L, et al. Incidence and spectrum of neonatal lupus erythematosus: a prospective study of infants born to mothers with anti-Ro autoantibodies. J Pediatr. 2003;142(6):678-83. doi: 10.1067/mpd.2003.233.
28. Llanos C, Izmirly PM, Katholi M, et al. Recurrence rates of cardiac manifestations associated with neonatal lupus and maternal/fetal risk factors. Arthritis Rheum. 2009;60(10):3091-7. doi: 10.1002/art.24768.
29. Friedman DM, Llanos C, Izmirly PM, et al. Evaluation of fetuses in a study of intravenous immunoglobulin as preventive therapy for congenital heart block: Results of a multicenter, prospective, open-label clinical trial. Arthritis Rheum. 2010;62(4):1138-46. doi: 10.1002/art.27308.
30. Pisoni CN, Brucato A, Ruffatti A, et al. Failure of intravenous immunoglobulin to prevent congenital heart block: Findings of a multicenter, prospective, observational study. Arthritis Rheum. 2010;62(4):1147-52. doi: 10.1002/art.27350.
31. Routsias JG, Kyriakidis NC, Friedman DM, et al. Association of the idiotype: antiidiotype antibody ratio with the efficacy of intravenous immunoglobulin treatment for the prevention of recurrent autoimmune-associated congenital heart block. Arthritis Rheum. 2011;63(9):2783-9. doi: 10.1002/art.30464.
32. Horn HC, Grau K, Junker P. IVIG treatment for progressive stroke in the primary antiphospholipid antibody syndrome. Lupus. 2004;13(6):478-80. doi: 10.1191/0961203303lu1035cr.
33. Штивельбанд ИБ, Кондратьева ЛВ, Решетняк ТМ. Применение внутривенного иммуноглобулина при тромбоцитопении у больных с антифосфолипидным синдромом. Научно-практическая ревматология. 2004;42(3):93-8 [Shtivel'band IB, Kondrat'eva LV, Reshetnyak TM. The use of intravenous immunoglobulin for thrombocytopenia in patients with antiphospholipid syndrome. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2004;42(3):93-8 (In Russ.)]. doi: 10.14412/1995-4484-2004-3-93-98.
34. Blank M, Anafi L, Zandman-Goddard G, et al. The efficacy of specific IVIG anti-idiotypic antibodies in antiphospholipid syndrome (APS): trophoblast invasiveness and APS animal model. Int Immunol. 2007;19(7):857-65. doi: 10.1093/intimm/dxm052.
35. Caccavo D, Vaccaro F, Ferri GM, et al. Antiidiotypes against antiphospholipid antibodies are present in normal polyspecific immunoglobulins for therapeutic use. J Autoimmun. 1994;7(4):537-48. doi: 10.1006/jaut.1994.1039.
36. Carreras LD, Perez GN, Vega HR, et al. Lupus anticoagulant and recurrent fetal loss: successful treatment with gammaglobulin. Lancet. 1988;2(8607):393-4. doi: 10.1016/S0140-6736(88)92859-0.
37. Branch DW, Peaceman AM, Druzin M, et al. A multicenter, placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy. The Pregnancy Loss Study Group. Am J Obstet Gynecol. 2000;182(1 Pt 1):122-7. doi: 10.1016/S0002-9378(00)70500-X.
38. Perricone R, De Carolis C, Krö egler B, et al. Intravenous immunoglobulin therapy in pregnant patients affected with systemic lupus erythematosus and recurrent spontaneous abortion. Rheumatology (Oxford). 2008;47(5):646-51. doi: 10.1093/rheumatology/ken046.
39. Решетняк ТМ. Новые возможности в лечении антифосфолипидного синдрома. Тромбоз, гемостаз и реология. 2012;2(50):33-43 [Reshetnyak TM. New possibilities in the treatment of antiphospholipid syndrome. Tromboz, gemostaz i reologiya = Thrombosis, hemostasis and rheology. 2012;2(50):33-43 (In Russ.)].
40. Насонов ЕЛ. Антифосфолипидный синдром. Москва: Литтерра; 2004. 440 с. [Nasonov EL. Antifosfolipidnyi sindrom [Antiphospholipid syndrome]. Moscow: Litterra; 2004. 440 p.].
41. Ruiz-Irastorza G, Khamashta MA. Lupus and pregnancy: integrating clues from the bench and bedside. Eur J Clin Invest. 2011;41(6):672-8. doi: 10.1111/j.1365-2362.2010.02443.x.
42. Sciascia S, Giachino O, Roccatello D. Prevention of thrombosis relapse in antiphospholipid syndrome patients refractory to conventional therapy using intravenous immunoglobulin. Clin Exp Rheumatol. 2012;30(3):409-13.
43. Макацария АД, Бицадзе ВО, Хизроева ДХ. Катастрофический антифосфолипидный синдром и тромботический «шторм». Сибирский медицинский журнал. 2010;25(4 выпуск 2);118-23 [Makatsariya AD, Bitsadze VO, Khizroeva DKh. Catastrophic antiphospholipid syndrome and thrombotic «storm». Sibirskii meditsinskii zhurnal = Siberian Medical Journal. 2010;25(4 issue 2);118-23 (In Russ.)].
44. Cervera R. Lessons from the «EuroPhospholipid» project. Autoimmun Rev. 2008;7(3):174-8. doi: 10.1016/j.autrev.2007.11.011.
45. Bucciarelli S, Cervera R, Espinosa G, et al. Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors. Autoimmun Rev. 2006;6(2):72-5. doi: 10.1016/j.autrev.2006.06.007.
46. Asherson RA, Cervera R, Piette JC, et al. Catastrophic antiphospholipid syndrome: clues to the pathogenesis from a series of 80 patients. Medicine (Baltimore). 2001;80(6):355-77. doi: 10.1097/00005792-200111000-00002.
47. Cervera R, Bucciarelli S, Plasin MA, et al. Catastrophic Antiphospholipid Syndrome (CAPS) Registry Project Group (European Forum On Antiphospholipid Antibodies). Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the «CAPS Registry». J Autoimmun. 2009;32(3-4):240-5. doi: 10.1016/j.jaut.2009.02.008.
48. Lapraik C, Watts R, Bacon P, et al. BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis. Rheumatology (Oxford). 2007;46(10):1615-6. doi: 10.1093/rheumatology/kem146a.
49. Martinez V, Cohen P, Pagnoux C, et al. Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: results of a multicenter, prospective, open-label study of twenty-two patients. Arthritis Rheum. 2008;58(1):308-17. doi: 10.1002/art.23147.
50. Fortin PM, Tejani AM, Bassett K, et al. Intravenous immunoglobulin as adjuvant therapy for Wegener’s granulomatosis. Cochrane Database Syst Rev. 2013;1:CD007057. doi: 10.1002/14651858.CD007057.pub3.
51. Levy Y, Sherer Y, George J, et al. Serological and clinical response to treatment of systemic vasculitis and associated autoimmune disease with intravenous immunoglobulin. Int Arch Allergy Immunol. 1999;119(3):231-8. doi: 10.1159/000024199.
52. Jayne DR, Lockwood CM. Intravenous immunoglobulin as sole therapy for systemic vasculitis. Br J Rheumatol. 1996;35(11):1150-3. doi: 10.1093/rheumatology/35.11.1150.
53. Richter C, Schnabel A, Csernok E, et al. Treatment of anti-neutrophii cytoplasmic antibody (ANCA)-associated systemic vasculitis with high-dose intravenous immunoglobulin. Clin Exp Immunol. 1995;101(1):2-7. doi: 10.1111/j.1365-2249.1995.tb02268.x.
54. Tsurikisawa N, Taniguchi M, Saito H, et al. Treatment of Churg-Strauss syndrome with high dose intravenous immunoglobulin. Ann Allergy Asthma Immunol. 2004;92(1): 80-7. doi: 10.1016/S1081-1206(10)61714-0.
55. Danieli MG, Cappelli M, Malcangi G, et al. Longterm effectiveness of intravenous immunoglobulin in Churg-Strauss syndrome. Ann Rheum Dis. 2004;63(12):1649-54. doi: 10.1136/ard.2003.015453.
56. Blank M, Levy Y, Amital H, et al. The role of intravenous immunoglobulin therapy in mediating skin fibrosis in tight skin mice. Arthritis Rheum. 2002;46(6):1689-90. doi: 10.1002/art.10363.
57. Asano Y, Ihn H, Asashima N, et al. A case of diffuse scleroderma successfully treated with high-dose intravenous immune globulin infusion. Rheumatology (Oxford). 2005;44(6):824-6. doi: 10.1093/rheumatology/keh600.
58. Molina V, Blank M, Shoenfeld Y. Intravenous immunoglobulin and fibrosis. Clin Rev Allergy Immunol. 2005;29(3):321-6. doi: 10.1385/CRIAI:29:3:321.
59. Cantarini L, Rigante D, Vitale A, et al. Intravenous immunoglobulins (IVIG) in systemic sclerosis: a challenging yet promising future. Immunol Res. 2015;61(3):326-37. doi: 10.1007/s12026-014-8615-z.
60. Nacci F, Righi A, Conforti ML, et al. Intravenous immunoglobulins improve the function and ameliorate join involvement in systemic sclerosis: a pilot study. Ann Rheum Dis. 2007;66(7):977-9. doi: 10.1136/ard.2006.060111.
61. Amital H, Rewald E, Levy Y, et al. Fibrosis regression induced by intravenous immunoglobulin treatment. Ann Rheum Dis. 2003;62(2):175-7. doi: 10.1136/ard.62.2.175.
62. Poelman CL, Hummers LK, Wigley FM, et al. Intravenous immunoglobulin may be an effective therapy for refractory, active diffuse cutaneous systemic sclerosis. J Rheumatol. 2015;42(2):236-42. doi: 10.3899/jrheum.140833.
63. Takehara K, Ihn H, Sato S. A randomized, double-blind, placebo-controlled trial: intravenous immunoglobulin treatment in patients with diffuse cutaneous systemic sclerosis. Clin Exp Rheumatol. 2013;31(2 Suppl 76):151-6.
64. Dalakas MC, Illa I, Dambrosia JM, et al. A controlled trial of high dose immune globulin infusions as treatment for dermatomyositis. N Engl J Med. 1993;329(27):1993-2000. doi: 10.1056/NEJM199312303292704.
65. Cherin P, Pelletier S, Teixeira A, et al. Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients. Arthritis Rheum. 2002;46(2):467-74. doi: 10.1002/art.10053.
66. Miyasaka N, Hara M, Koike T, et al. Effects of intravenous immunoglobulin therapy in Japanese patients with polymyositis and dermatomyositis resistant to corticosteroids: a randomized double-blind placebo-controlled trial. Mod Rheumatol. 2012;22(3):382-93. doi: 10.1007/s10165-011-0534-4.
67. Tsai MJ, Lai CC, Lin SC, et al. Intravenous immunoglobulin therapy in juvenile dermatomyositis. Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi. 1997;38(2):111-5.
68. Al-Mayouf SM, Laxer RM, Schneider R, et al. Intravenous immunoglobulin therapy for juvenile dermatomyositis: efficacy and safety. J Rheumatol. 2000;27(10):2498-503.
69. Furusho K, Sato K, Soeda T, et al. Highdose intravenous gammaglobulin for Kawasaki disease. Lancet. 1983;2(8363):1359. doi: 10.1016/S0140-6736(83)91109-1.
70. Oates-Whitehead RM, Baumer JH, Haines L, et al. Intravenous immunoglobulin for the treatment of Kawasaki disease in children. Cochrane Database Syst Rev. 2003;(4):CD004000. doi: 10.1002/14651858.cd004000.
71. Silverman ED, Laxer RM, Greenwald M, et al. Intravenous gamma globulin therapy in systemic juvenile rheumatoid arthritis. Arthritis Rheum. 1990;33(7):1015-22. doi: 10.1002/art.1780330714.
72. Silverman ED, Cawkwell GD, Lovell DJ, et al. Intravenous immunoglobulin in the treatment of systemic juvenile rheumatoid arthritis: a randomised placebo controlled trial. J Rheumatol. 1994;21(12):2353-8.
73. Emery P, Spath P, Affentranger P. A placebo controlled double blind study of high dose intravenous immunoglobulin therapy in patients with early rheumatoid arthritis. Arthritis Rheum. 1996;39:1027-9. doi: 10.1002/art.1780390621.
74. Kanik KS, Yarboro CH, Naparstek Y, et al. Failure of low-dose intravenous immunoglobulin therapy to suppress disease activity in patients with treatment-refractory rheumatoid arthritis. Arthritis Rheum. 1996;39(6):1027-9. doi: 10.1002/art.1780390621.
75. Zeuner RA, Schroeder JO, Schrö der F, et al. Successful application of high dose intravenous immunoglobulins in Sjogren’s syndrome associated arthritis. Ann Rheum Dis. 1995;54(11):936. doi: 10.1136/ard.54. 11.936-a.
76. Rajabally YA, Seow H, Abbott RJ. Immunoglobulin-responsive dysautonomia in Sjogren’s syndrome. J Neurol. 2007;254(5): 674-5. doi: 10.1007/s00415-006-0378-6.
77. Smith AJ, Jackson MW, Wang F, et al. Neutralization of muscarinic receptor autoantibodies by intravenous immunoglobulin in Sjogren syndrome. Hum Immunol. 2005;66(4):411-6. doi: 10.1016/j.humimm.2005.01.020.
78. Seider N, Beiran I, Scharf J, et al. Intravenous immunoglobulin therapy for resistant ocular Behcet's disease. Br J Ophthalmol. 2001;85(11):1287-8. doi: 10.1136/bjo.85.11.1287.
Рецензия
Для цитирования:
Середавкина НВ, Решетняк ТМ, Насонов ЕЛ. Место внутривенного иммуноглобулина при ревматических заболеваниях. Современная ревматология. 2015;9(4):59-67. https://doi.org/10.14412/1996-7012-2015-4-59-67
For citation:
Seredavkina NV, Reshetnyak TM, Nasonov EL. The place of intravenous immunoglobulin in rheumatic diseases. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2015;9(4):59-67. (In Russ.) https://doi.org/10.14412/1996-7012-2015-4-59-67
Просмотров:
1398
Послать статью по эл. почте 